Seattle-based biotech company Seagen recently released early findings from a trial of its drug Padcev in combination with Merck’s Keytruda to treat patients with specific forms of urothelial cancer.
The data surpassed researchers’ bar for success with a 64.5 percent response rate, indicating a possible fast-track to FDA approval. Padcev is currently in development for various forms and settings of bladder cancer and involved in a solid tumor trial as well.